"In our industry, quality and risk management parameters are integrated into all aspects of research, development, production and application, as our products must perform flawlessly. Dyadem's software allows us to work in a more uniform environment, and assess quality in a standard way. Our focus on increasing quality and minimizing potential risks has, in turn, favorable impact on time to market as well as reduce post-launch complaints," said Lisa Robertson, Director, Design and Development, Quality Assurance.
By achieving the high standards of quality, minimizing the risk of defects and reducing process administration, Dyadem is helping Genzyme maintain its status as an industry leader in medical research and device production.
"Achieving reduced risk through a comprehensive standard of quality should be at the top of the list for every company. In Genzyme's important industry of developing life-saving technologies, there is no room for error," said Kevin North, president and CEO of Dyadem. "Genzyme is setting an example by highlighting the importance of quality lifecycle management. Our software allows Genzyme to continue operating at an elite level to develop these life- altering technologies in an environment with high quality standards."
Founded in 1993, Dyadem is the market leader in Quality Lifecycle
Management and Risk Lifecycle Management solutions. Dyadem provides
software and services that empower companies to manage quality, mitigate
risks, achieve regulatory compliance
Copyright©2008 PR Newswire.
All rights reserved